Aquinox Pharmaceuticals Announces Third Quarter 2018 Financial Results

Aquinox Pharmaceuticals (NASDAQ:AQXP), a pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today...

Aquinox Announces Topline Results of Phase 3 LEADERSHIP 301 Clinical Trial in Interstitial Cystitis/Bladder Pain Syndrome

Aquinox Pharmaceuticals (NASDAQ:AQXP), today announced that the Phase 3 LEADERSHIP 301 clinical trial evaluating once-daily, oral rosiptor (AQX-1125) for the treatment...